Safety and Pharmacokinetics of High-Dose TAS-303 in Healthy Japanese Volunteers: A Single-Center, Single-Blind, Randomized, Placebo-Controlled, Parallel-Group Multiple-Ascending-Dose Study

被引:3
作者
Hanada, Ryuzo [1 ]
机构
[1] SOUSEIKAI Sumida Hosp, Tokyo, Japan
关键词
pharmacokinetics; phase; 1; study; safety; TAS-303; multiple-ascending-dose study; CYP3A ACTIVITY; INHIBITION; CLEARANCE;
D O I
10.1002/cpdd.801
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Preclinical data of TAS-303 (4-piperidinyl 2,2-diphenyl-2-[propoxy-1,1,2,2,3,3,3-d(7)] acetate hydrochloride), a noradrenaline reuptake inhibitor, show that it increases urethral contraction in rats and may therefore benefit stress urinary incontinence patients. In this single-blind, randomized, placebo-controlled, parallel-group, multiple-ascending-dose phase 1 study, we evaluated the safety and tolerability of once-daily TAS-303 8, 10, 12, 15, or 18 mg administered for 16 days in healthy subjects. In addition, we investigated the pharmacokinetics and inhibitory effect of TAS-303 on hepatic cytochrome P450 (CYP) 3A activity. Rates of adverse events, adverse drug reactions, and pharmacokinetic parameters of TAS-303 were evaluated. Fifty subjects were randomized: 7 subjects each were assigned to receive TAS-303 8-18 mg, and 3 subjects each were assigned to receive placebo at each dose. The overall incidences of adverse events and adverse drug reactions in all subjects administered TAS-303 (n = 35) was 25.7% and 2.9%, respectively, and those for the placebo groups (n = 15) were 46.7% and 0%, respectively. No deaths or serious adverse events occurred. TAS-303 displayed a dose-proportional pharmacokinetic profile across doses of 8-18 mg over the 16-day multiple administration period, and TAS-303 might inhibit hepatic CYP3A activity within this dose range. TAS-303 at a dose of 8-18 mg was confirmed to be safe and tolerable.
引用
收藏
页码:961 / 971
页数:11
相关论文
共 12 条
[1]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[2]   The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction [J].
D'Ancona, Carlos ;
Haylen, Bernard ;
Oelke, Matthias ;
Abranches-Monteiro, Luis ;
Arnold, Edwin ;
Goldman, Howard ;
Humid, Rizwan ;
Homma, Yukio ;
Marcelissen, Tom ;
Rademakers, Kevin ;
Schizas, Alexis ;
Singla, Ajay ;
Soto, Irela ;
Tse, Vincent ;
de Wachter, Stefan ;
Herschorn, Sender .
NEUROUROLOGY AND URODYNAMICS, 2019, 38 (02) :433-477
[3]   Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine [J].
DeWitt, Sheila H. ;
Maryanoff, Bruce E. .
BIOCHEMISTRY, 2018, 57 (05) :472-473
[4]   Evidence for the validity of cortisol 6β-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans [J].
Furuta, T ;
Suzuki, A ;
Mori, C ;
Shibasaki, H ;
Yokokawa, A ;
Kasuya, Y .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (11) :1283-1287
[5]  
Harbeson SL., 2014, Medchem News, V24, P8, DOI DOI 10.14894/MEDCHEM.24.2_8
[6]   Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study [J].
Irwin, Debra E. ;
Milsom, Ian ;
Hunskaar, Steinar ;
Reilly, Kate ;
Kopp, Zoe ;
Herschorn, Sender ;
Coyne, Karin ;
Kelleher, Con ;
Hampel, Christian ;
Artibani, Walter ;
Abrams, Paul .
EUROPEAN UROLOGY, 2006, 50 (06) :1306-1315
[7]   Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects [J].
Kasichayanula, Sreeneeranj ;
Boulton, David W. ;
Luo, Wen-Lin ;
Rodrigues, A. David ;
Yang, Zheng ;
Goodenough, Angela ;
Lee, Michelle ;
Jemal, Mohammed ;
LaCreta, Frank .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (05) :1122-1134
[8]   A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver [J].
Kumagai, Yuji ;
Fujita, Tomoe ;
Maeda, Mika ;
Sasaki, Yoshinobu ;
Nagaoka, Makoto ;
Huang, Jinhong ;
Takenaka, Toru ;
Kawai, Masaki .
JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (06) :702-710
[9]  
Kwon Bo Eun, 2010, Int Neurourol J, V14, P133, DOI 10.5213/inj.2010.14.3.133
[10]   TAS-303, a Novel Selective Norepinephrine Reuptake Inhibitor that Increases Urethral Pressure in Rats, Indicating Its Potential as a Therapeutic Agent for Stress Urinary Incontinence [J].
Mizutani, Hiroya ;
Sakakibara, Fukumitsu ;
Komuro, Masahito ;
Sasaki, Eiji .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2018, 366 (02) :322-331